Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 1
1957 4
1958 2
1959 2
1962 1
1964 3
1967 1
1968 3
1969 1
1970 2
1971 1
1972 2
1973 1
1974 2
1975 30
1976 26
1977 30
1978 25
1979 19
1980 40
1981 41
1982 31
1983 40
1984 59
1985 58
1986 55
1987 44
1988 72
1989 74
1990 80
1991 87
1992 78
1993 88
1994 81
1995 74
1996 87
1997 72
1998 102
1999 97
2000 100
2001 109
2002 108
2003 104
2004 137
2005 134
2006 93
2007 129
2008 115
2009 151
2010 142
2011 180
2012 180
2013 224
2014 215
2015 183
2016 197
2017 184
2018 197
2019 220
2020 232
2021 259
2022 274
2023 269
2024 122

Text availability

Article attribute

Article type

Publication date

Search Results

5,202 results

Results by year

Filters applied: . Clear all
Page 1
The history of haemophilia - a short review.
Schramm W. Schramm W. Thromb Res. 2014 Nov;134 Suppl 1:S4-9. doi: 10.1016/j.thromres.2013.10.020. Epub 2014 Feb 7. Thromb Res. 2014. PMID: 24513149 Review.
The availability of pasteurized, and therefore virus-safe, plasma-derived, clotting factor concentrates, such as Haemate P() and Beriate() P in Germany and other countries, dramatically improved the quality of life and life expectancy of haemophilia patients. ...
The availability of pasteurized, and therefore virus-safe, plasma-derived, clotting factor concentrates, such as Haemate P() and Beri …
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DV, Symington E, Leavitt AD, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele KM, Reddy DB, Henshaw J, Robinson TM, Wong WY, Pipe SW; GENEr8-1 Trial Group. Mahlangu J, et al. N Engl J Med. 2023 Feb 23;388(8):694-705. doi: 10.1056/NEJMoa2211075. N Engl J Med. 2023. PMID: 36812433 Clinical Trial.
BACKGROUND: Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a phase 3 study of the efficacy and safety of valoctocogene …
BACKGROUND: Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prev …
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, Tran H, Sun J, Wu R, Poloskey S, Qiu Z, Kichou S, Andersson S, Mei B, Rangarajan S. Young G, et al. Lancet. 2023 Apr 29;401(10386):1427-1437. doi: 10.1016/S0140-6736(23)00284-2. Epub 2023 Mar 29. Lancet. 2023. PMID: 37003287 Clinical Trial.
Negative binomial model-based mean annualised bleeding rate was significantly lower in the fitusiran prophylaxis group (1.7 [95% CI 1.0-2.7]) than in the bypassing agents on-demand group (18.1 [10.6-30.8]), corresponding to a 90.8% (95% CI 80.8-95.6) reduction in annualised bleed …
Negative binomial model-based mean annualised bleeding rate was significantly lower in the fitusiran prophylaxis group (1.7 [95% CI 1.0-2.7] …
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, Pasi KJ. Rangarajan S, et al. N Engl J Med. 2017 Dec 28;377(26):2519-2530. doi: 10.1056/NEJMoa1708483. Epub 2017 Dec 9. N Engl J Med. 2017. PMID: 29224506 Free article. Clinical Trial.
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the central nervous system. Although successful gene transfer has been reported in patients with hemophilia B, the large size of the factor VIII codi …
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the centr …
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, Hardesty B, Shima M, Pollock T, Slev P, Oldenburg J, Ozelo MC, Stieltjes N, Castet SM, Mahlangu J, Peyvandi F, Kazmi R, Schved JF, Leavitt AD, Callaghan M, Pan-Petesch B, Quon DV, Andrews J, Trinh A, Li M, Wong WY. Klamroth R, et al. Hum Gene Ther. 2022 Apr;33(7-8):432-441. doi: 10.1089/hum.2021.287. Epub 2022 Mar 16. Hum Gene Ther. 2022. PMID: 35156839 Free PMC article.
Adeno-associated virus (AAV)-mediated gene therapy may provide durable protection from bleeding events and reduce treatment burden for people with hemophilia A (HA). However, pre-existing immunity against AAV may limit transduction efficiency and hence treatment suc …
Adeno-associated virus (AAV)-mediated gene therapy may provide durable protection from bleeding events and reduce treatment burden for peopl …
Twenty years of treatment with Beriate P.
Brackmann HH. Brackmann HH. Thromb Res. 2014 Nov;134 Suppl 1:S1-3. doi: 10.1016/j.thromres.2013.10.011. Epub 2013 Dec 21. Thromb Res. 2014. PMID: 24360930 No abstract available.
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R. Seth Chhabra E, et al. Blood. 2020 Apr 23;135(17):1484-1496. doi: 10.1182/blood.2019001292. Blood. 2020. PMID: 32078672 Free PMC article.
Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII levels. ...BIV …
Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia …
Advances in gene therapy for hemophilia.
Robles-Rodriguez OA, Pe Rez-Trujillo JJ, Villanueva-Olivo A, Villarreal-Martinez L, Marfil-Rivera LJ, Rodriguez-Rocha H, Garcia-Garcia A, Saucedo-Cardenas O, Loera-Arias MJ, Oca-Luna RM. Robles-Rodriguez OA, et al. J Biosci. 2020;45:88. J Biosci. 2020. PMID: 32661215 Free article. Review.
Hemophilia A.
Hoyer LW. Hoyer LW. N Engl J Med. 1994 Jan 6;330(1):38-47. doi: 10.1056/NEJM199401063300108. N Engl J Med. 1994. PMID: 8259143 Review. No abstract available.
A review of immune tolerance induction with Haemate P in haemophilia A.
Escuriola Ettingshausen C, Kreuz W. Escuriola Ettingshausen C, et al. Haemophilia. 2014 May;20(3):333-9. doi: 10.1111/hae.12288. Epub 2013 Oct 24. Haemophilia. 2014. PMID: 24165472 Free article. Review.
We performed a literature search to identify reports from January 1980 to October 2012 on the use of the plasma-derived, von Willebrand factor (VWF)-containing FVIII concentrate Haemate P/Humate-P in the setting of ITI. Six reports were identified that specifically …
We performed a literature search to identify reports from January 1980 to October 2012 on the use of the plasma-derived, von Willebrand fact …
5,202 results